Lisata Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Lisata Therapeutics, Inc. on June 10, 2025. The filing discloses the execution of amended and restated employment and separation benefits agreements with key executive officers and former officers. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol LSTA.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation arrangements.
Material Changes and Executive Compensation
On June 10, 2025, the Company entered into new agreements with the following individuals:
- David J. Mazzo, Ph.D. (CEO): Base salary increased from $633,032 to $717,229. The $12,000 annual non-accountable expense allowance was removed. The agreement clarifies "Good Reason" to include material salary reductions and modifies Change in Control (CIC) determination authority to the pre-CIC board.
- Kristen K. Buck, M.D. (VP, R&D and CMO): Base salary increased from $550,000 to $599,342. Similar to Dr. Mazzo, the agreement clarifies "Good Reason" and CIC determination authority. Bonus payments upon termination not connected to a CIC will no longer be pro-rated.
- James Nisco (SVP Finance and CAO): Entered into an amended separation benefits agreement. The definition of CIC was updated to include shareholder approval of a complete liquidation plan. Severance rights are now explicitly conditioned on the timely execution of a general release of claims.
- Tariq Imam (SVP Business Development and General Counsel): Entered into an amended separation benefits agreement. Current base salary is $356,000. Severance terms include 12 months of salary continuation, 100% of the annual target bonus, and COBRA coverage. The agreement also mandates full vesting of unvested equity awards upon qualifying termination.
Common amendments across all agreements include:
- Updating the definition of "Change in Control" to include shareholder-approved liquidation plans compliant with Treasury Regulation §1.409A-3(i)(5).
- Modifying COBRA benefit coverage to monthly reimbursement payments, with a lump-sum cash alternative if the plan is terminated or tax penalties would apply.
- Clarifying compliance with Section 409A of the Internal Revenue Code regarding severance payment timing and limits.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, operational outlook, or management commentary on business strategy. The primary risk disclosed relates to the potential future cash outflows associated with the enhanced severance and separation benefits for the named executives in the event of termination or a Change in Control.
Key Facts for Investor Verification
- Verify the total annualized increase in fixed compensation costs for the CEO and CMO resulting from the salary adjustments.
- Review the full text of the separation agreements (Exhibits 10.3 and 10.4) to understand the specific financial liabilities triggered by a Change in Control or termination without Cause.
- Confirm the status of Tariq Imam's employment, as the filing details separation benefits which may imply an impending or recent departure.
- Check the Company's most recent 10-K or 10-Q for current cash balances to assess the ability to fund potential severance obligations.